NCT04259086View on ClinicalTrials.gov

Efficacy and Safety of DaxibotulinumtoxinA (DAXI) for Injection for Treatment of Upper Facial Lines

PHASE2CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

December 6, 2019

Primary Completion Date

November 2, 2020

Study Completion Date

November 2, 2020

Conditions
Upper Facial Lines (Glabellar Lines, Forehead Lines, & Lateral Canthal Lines)
Interventions
DRUG

DaxibotulinumtoxinA for injection

Intramuscular injection

Trial Locations (8)

10028

Site 6, New York

33146

Site 5, Coral Gables

90266

Site 1, Manhattan Beach

90404

Site 7, Santa Monica

92121

Site 3, San Diego

02467

Site 2, Chestnut Hill

V5Z 4E1

Site 4, Vancouver

M5R3N8

Site 8, Toronto

All Listed Sponsors
lead

Revance Therapeutics, Inc.

INDUSTRY

NCT04259086 - Efficacy and Safety of DaxibotulinumtoxinA (DAXI) for Injection for Treatment of Upper Facial Lines | Biotech Hunter | Biotech Hunter